Breakthroughs in Huntington’s Disease: Essential Insights on Gene Therapy

Innovative gene therapy has emerged as the pioneering treatment that effectively slows the progression of Huntington’s disease. While the results are still in their early stages, this method holds significant promise and could even pave the way for new therapies for other neurodegenerative disorders, including Parkinson’s and Alzheimer’s diseases.

How does the treatment function?

The therapy known as AMT-130 specifically targets the abnormal brain proteins associated with Huntington’s disease progression. Those affected by the condition possess genetic mutations that result in the accumulation of huntingtin proteins, which form toxic aggregates in brain cells, leading to cell death. This eventually manifests as memory loss, mobility issues, speech impairment, and various other symptoms.

Therapies from the Dutch biopharmaceutical company Uniqure aim to halt the production of these mutant proteins. The process involves delivering genetic material to brain cells using a harmless virus. This genetic material instructs the cells to produce small RNA molecules called microRNAs that effectively block and eliminate the signals that lead to the generation of toxic proteins. It acts similarly to a molecular stop signal.

Procedures and Location of Treatment

This therapy initially focuses on two specific brain areas impacted by Huntington’s disease: the caudate nucleus and the putamen. These regions are located deep within the brain, requiring doctors to utilize real-time brain imaging to navigate thin catheters into place. The entire procedure duration ranges from 12 to 18 hours, and preliminary results suggest that a single injection may be adequate to permanently reduce levels of mutant huntingtin in the brain.

What is the efficacy of gene therapy?

Initial findings released by Uniqure indicate that gene therapy may slow the advancement of Huntington’s disease by approximately 75%.

The revelation stems from a clinical trial spearheaded by Sarah Tabrizi of University College London, where 17 Huntington patients received high-dose treatment. After three years, researchers noted the deterioration in cognitive function, motor skills, and daily activities compared to a similar group of untreated individuals. Tabrizi remarked that the decline typically observed over a year in untreated patients was instead noted within four years for those receiving treatment. BBC News. Additionally, those treated exhibited reduced levels of proteins associated with brain damage in their cerebrospinal fluid, highlighting the potential of gene therapy in slowing Huntington’s progression.

“These findings reaffirm our conviction that AMT-130 could revolutionize the treatment landscape for Huntington’s disease,” stated Walid Abi-Saad from Uniqure in a press release.

Are there any side effects?

While Uniqure has not provided comprehensive data on the side effects of the treatment, initial reports suggest that the drug appears to be safe and well-tolerated. The most frequently reported side effects included headaches and confusion, which generally resolved with steroid treatment to reduce inflammation.

When will the treatment be accessible?

In a recent press announcement, Uniqure indicated that it anticipates submitting an application to the U.S. Food and Drug Administration early next year, with the potential for product availability as soon as before 2027 with expedited approval.

“However, it is still in the preliminary phase, and further testing is necessary to assess the long-term effects of this new gene therapy and any potential side effects,” noted Zofia Miedzybrodzka from the University of Aberdeen, UK, in a statement.

Could this method assist in treating other brain disorders?

If successful, the gene therapy could facilitate the development of analogous treatments for various neurodegenerative diseases, including Parkinson’s and other forms of dementia, according to David Rubinsztein from Cambridge University. Researchers could manipulate genetic material to target the toxic proteins that cause these conditions. “This could represent a significant breakthrough,” he remarked.